Alzheimer’s dementia: pathogenesis and impact of cardiovascular risk factors on cognitive decline
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common form of dementia manifesting as alterations in cognitive abilities, behavior, and deterioration in memory which is progressive, leading to gradual worsening of symptoms. Major pathological features of AD are accumulations of neuronal amyloid plaques and neurofibrillary tangles, with early lesions appearing primarily in the hippocampus, the area of the brain involved in memory and learning. Cardiovascular-related risk factors are believed to play a crucial role in disease development and the acceleration of cognitive deterioration by worsening cerebral perfusion, promoting disturbances in amyloid clearance. Current evidence supports hypertension, hypotension, heart failure, stroke and coronary artery diseases as potential factors playing a role in cognitive decline in patients with Alzheimer's dementia. Although dementia due to cardiovascular deficits is more strongly linked to the development of vascular dementia, a stepwise decline in cognition, recent researches have also discovered its deleterious influence on AD development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Debette, S., & Markus, H. S. (2010) · BMJ · doi:10.1136/bmj.c3666 · Cited by 2,328 · cited 1×
“However, whether changes in white matter really explains the clinical picture of AD is still unclear since some studies proved no relationship between them [36,37].”
BackgroundIncidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051 · cited 1×
“Due to better patient education, more effective treatments and therapeutic interventions targeting upstream vascular risk factors, dementia incidence is decreasing [2,3].”
BackgroundIadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Kivipelto, M., Solomon, A., Ahtiluoto, S., Ngandu, T., Lehtisalo, J., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.09.012 · Cited by 589 · cited 1×
“delaying the onset and prevention of cognitive impairment [4].”
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545 · cited 1×
“However, a recent randomized trial on a drug targeting Aβ failed to show any cognitive benefits [24].”
BackgroundLee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24647 · Cited by 542
The antimicrobial protection hypothesis of Alzheimer’s disease
Moir, R. D., Lathe, R., & Tanzi, R. E. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3040 · Cited by 456
Cerebral amyloid angiopathy pathology and cognitive domains in older persons
Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2011) · Annals of Neurology · doi:10.1002/ana.22112 · Cited by 383 · cited 1×
“These neuropathological alterations are known as cerebral amyloid angiopathy (CAA) [16,17], which has been discovered to play an independent role in worsening cognitive impairment in AD patients with pre-existing pathological AD lesions [18].”
BackgroundStroke and dementia risk: A systematic review and meta‐analysis
Kuźma, E., Lourida, I., Moore, S. F., Levine, D. A., Ukoumunne, O. C., & Llewellyn, D. J. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3061 · Cited by 376
Faraco, G., Sugiyama, Y., Lane, D., Garcia-Bonilla, L., Chang, H., Santisteban, M. M., Racchumi, G., Murphy, M., Van Rooijen, N., Anrather, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86950 · Cited by 350 · cited 2×
“Perivascular macrophages are macrophages that reside in the perivascular space surrounding vessels of the brain, and through their generation of reactive oxygen species (ROS), can induce oxidative stress [63,64].”
BackgroundCerebral Blood Flow in Patients With Chronic Heart Failure Before and After Heart Transplantation
Gruhn, N., Larsen, F. S., Boesgaard, S., Knudsen, G. M., Mortensen, S. A., Thomsen, G., & Aldershvile, J. (2001) · Stroke · doi:10.1161/hs1101.098360 · Cited by 304 · cited 11×
“As we age, a study assessing the cerebral blood flow/ cardiac output index in subjects of age 21–80 found a 1.3% decline in the ratio per decade, suggesting a decrease in cerebral blood flow (CBF) in the normal aging process [30].”
BackgroundInfluentialSadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Wolters, F. J., Segufa, R. A., Darweesh, S. K. L., Bos, D., Ikram, M. A., Sabayan, B., Hofman, A., & Sedaghat, S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.007 · Cited by 293 · cited 1×
“Associations have been made between atherosclerosis, CAD and development of dementia [68,69].”
BackgroundTherapy insight, type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease
Haan, M. N. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0124 · Cited by 284 · cited 1×
“Besides hypertension, obesity also contributes to insulin resistance and inflammation, influencing neurogenerative processes [89,90].”
BackgroundUncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study
Xu, W. L., von Strauss, E., Qiu, C. X., Winblad, B., & Fratiglioni, L. (2009) · Diabetologia · doi:10.1007/s00125-009-1323-x · Cited by 272
Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Aβ Peptides
Park, L., Uekawa, K., Garcia-Bonilla, L., Koizumi, K., Murphy, M., Pistik, R., Younkin, L., Younkin, S., Zhou, P., Carlson, G., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311054 · Cited by 259
Mossello, E., Pieraccioli, M., Nesti, N., Bulgaresi, M., Lorenzi, C., Caleri, V., Tonon, E., Cavallini, M. C., Baroncini, C., Di Bari, M., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8164 · Cited by 247
The impact of obesity on neurodegenerative diseases.
Mazon, J. N., de Mello, A. H., Ferreira, G. K., & Rezin, G. T. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.06.002 · Cited by 185 · cited 1×
“Besides hypertension, obesity also contributes to insulin resistance and inflammation, influencing neurogenerative processes [89,90].”
BackgroundDistribution of cardiac output to the brain across the adult lifespan
Xing, C.-Y., Tarumi, T., Liu, J., Zhang, Y., Turner, M., Riley, J., Tinajero, C. D., Yuan, L.-J., & Zhang, R. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16676826 · Cited by 160
Faraco, G., Park, L., Zhou, P., Luo, W., Paul, S. M., Anrather, J., & Iadecola, C. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.79 · Cited by 158 · cited 2×
“Moreover, ATII exacerbates the pre-existing AD pathology since it upregulates the enzymes β- and γ- secretase [51,54] which cleaves APP into Aβ-amyloid, and activates the tau kinase GSK3β [55] resulting in greater amounts of amyloid deposits and hyperphosphorylated tau inducing further damage [Figure 1].”
BackgroundCerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
Castillo-Carranza, D. L., Nilson, A. N., Van Skike, C. E., Jahrling, J. B., Patel, K., Garach, P., Gerson, J. E., Sengupta, U., Abisambra, J., Nelson, P., et al. (2017) · Aging and disease · doi:10.14336/ad.2017.0112 · Cited by 118
Li, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Ye, X., Feng, T., Tammineni, P., Chang, Q., Jeong, Y. Y., Margolis, D. J., Cai, H., Kusnecov, A., & Cai, Q. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2851-16.2017 · Cited by 70
Cited by
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Huang, L.-K., Kuan, Y.-C., Lin, H.-W., & Hu, C.-J. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00976-6 · Cited by 252
“Vascular risk factors can also lead to inflammation in the brain, which damages neuronal cells and further increases the likelihood of AD dementia [34].”
BackgroundGarcía-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Herpes Zoster Does Not Increase the Risk of Neurodegenerative Dementia: A Case-Control Study
Choi, H. G., Park, B. J., Lim, J. S., Sim, S. Y., Jung, Y. J., & Lee, S. W. (2021) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/15333175211006504 · Cited by 34
“Neurodegenerative dementia is 3 times more prevalent than vascular dementia.(2,3) Variable infectious pathogens, including human immunodeficiency virus, herpes virus, toxoplasmosis, cryptococcus, cytomegalovirus, and syphilis, are known to be causes of dementia.”
BackgroundGonzález-Cidad, A., García-Moncó, J. C., & Román, G. C. (2026) · Medicina · doi:10.3390/medicina62040696 · Cited by 1
Metadata
- Authors
- Wanleenuwat, P., Iwanowski, P., & Kozubski, W.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2019-08-27
- Volume
- 131
- Issue
- 7
- Pages
- 415-422
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2969420186
- Cited by
- 58
- References
- 23
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.